AcelRx Pharmaceuticals (ACRX) Posts Narrower than Expected Q4 Loss of 33c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q4 EPS of ($0.33), $0.06 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c